A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Johnson & Johnson and its subsidiaries (the Company) have approximately 138,200 employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the healthcare field. Johnson & Johnson is a holding company, with operating companies conducting business in virtually all countries of the world. The Company’s primary focus is products related to human health and well-being. Johnson & Johnson was incorporated in the State of New Jersey in 1887. The Chief Operating Decision Maker (CODM) is the Company's Chief Executive Officer (Principal Executive Officer). The Executive Committee is Johnson & Johnson’s senior leadership team responsible for setting the strategy and priorities of the Company and driving accountability at all levels. Within the strategic parameters provided by the Executive Committee, senior management groups at U.S.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 94.2B | 94.2B | 88.8B | 80.0B | 93.8B | 82.6B |
| Net Income | 26.8B | 26.8B | 14.1B | 17.9B | 20.9B | 14.7B |
| EPS | $11.03 | $11.03 | $5.79 | $6.73 | $7.81 | $5.51 |
| Free Cash Flow | 19.7B | 19.7B | 19.8B | 17.2B | 19.8B | 20.2B |
| ROIC | 24.7% | 28.3% | 17.2% | 23.4% | 16.7% | 13.1% |
| Gross Margin | 67.9% | 67.9% | 69.1% | 69.3% | 68.2% | 65.6% |
| Debt/Equity | 0.61 | 0.61 | 0.54 | 0.45 | 0.39 | 0.37 |
| Dividends/Share | $5.09 | $5.14 | $4.91 | $4.70 | $4.45 | $4.19 |
| Operating Income | 33.6B | 33.6B | 17.4B | 21.2B | 23.0B | 16.7B |
| Operating Margin | 35.6% | 35.6% | 19.6% | 26.5% | 24.5% | 20.2% |
| ROE | 32.9% | 35.0% | 19.7% | 26.1% | 18.5% | 14.5% |
| Shares Outstanding | 2,430M | 2,430M | 2,429M | 2,666M | 2,673M | 2,670M |
JOHNSON & JOHNSON passes 6 of 9 quality checks, suggesting mixed fundamentals.
JOHNSON & JOHNSON trades at 21.6x trailing earnings, compared to its 15-year median P/E of 20.5x, suggesting it is currently Fair relative to its historical range. On a free-cash-flow basis, the stock trades at 29.1x vs a median of 19.9x. The company's 5-year average ROIC is 19.7% with a gross margin of 68.0%. Total shareholder yield (dividends + buybacks) is 3.2%. At current prices, the estimated annualized return to fair value is +5.7%.
JOHNSON & JOHNSON (JNJ) has a current P/E ratio of 21.6, compared to its historical median P/E of 20.5. The stock is currently considered Fair based on its historical valuation range.
JOHNSON & JOHNSON (JNJ) has a 5-year average return on invested capital (ROIC) of 19.7%. This indicates strong capital allocation and a potential competitive advantage.
JOHNSON & JOHNSON (JNJ) has a market capitalization of $578.3B. It is classified as a mega-cap stock.
Yes, JOHNSON & JOHNSON (JNJ) pays a dividend with a trailing twelve-month yield of 2.14%. The company also returns capital through share buybacks, with a buyback yield of 1.03%.
Based on historical P/E analysis, JOHNSON & JOHNSON (JNJ) appears fair. The current P/E of 21.6 is 5% above its historical median of 20.5. The estimated fair value CAGR (P/E method) is 13.0%.
JOHNSON & JOHNSON (JNJ) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
JOHNSON & JOHNSON (JNJ) reported annual revenue of $94.2 billion in its most recent fiscal year, based on SEC EDGAR filings.
JOHNSON & JOHNSON (JNJ) has a net profit margin of 28.5%. This is a strong margin indicating high profitability.
JOHNSON & JOHNSON (JNJ) generated $19.7 billion in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
JOHNSON & JOHNSON (JNJ) has a debt-to-equity ratio of 0.61. This indicates moderate leverage.
JOHNSON & JOHNSON (JNJ) reported earnings per share (EPS) of $11.03 in its most recent fiscal year.
JOHNSON & JOHNSON (JNJ) has a return on equity (ROE) of 35.0%. This indicates the company generates strong returns for shareholders.
JOHNSON & JOHNSON (JNJ) has a 5-year average gross margin of 68.0%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 19 years of financial data for JOHNSON & JOHNSON (JNJ), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
JOHNSON & JOHNSON (JNJ) has a book value per share of $33.56, based on its most recent annual SEC filing.